Nivo-Cabo Combo Joins Advanced RCC Treatment Ranks Nivo-Cabo Combo Joins Advanced RCC Treatment Ranks
The PD-1 inhibitor/TKI combination is the latest to show superior survival in comparison with sunitinib as first-line therapy for patients with metastatic renal cell carcinoma (RCC).Medscape Medical News
Source: Medscape Urology Headlines - Category: Urology & Nephrology Tags: Hematology-Oncology News Source Type: news
More News: Cancer & Oncology | Carcinoma | Hematology | Kidney Cancer | Renal Cell Carcinoma | Urology & Nephrology